Catherine Jankowski
Concepts (364)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 41 | 2026 | 2213 | 5.230 |
Why?
| | HIV Infections | 42 | 2026 | 3215 | 4.050 |
Why?
| | Caregivers | 7 | 2026 | 1080 | 2.300 |
Why?
| | Frailty | 9 | 2026 | 208 | 2.190 |
Why?
| | Body Composition | 17 | 2026 | 689 | 1.750 |
Why?
| | Art Therapy | 2 | 2025 | 24 | 1.590 |
Why?
| | Exercise Therapy | 11 | 2026 | 488 | 1.500 |
Why?
| | Self-Management | 2 | 2025 | 207 | 1.450 |
Why?
| | Neoplasms | 8 | 2025 | 2954 | 1.370 |
Why?
| | Motivation | 6 | 2024 | 605 | 1.320 |
Why?
| | Heart Failure | 5 | 2026 | 2329 | 1.170 |
Why?
| | Dehydroepiandrosterone | 3 | 2018 | 50 | 1.130 |
Why?
| | Bone Density | 8 | 2021 | 494 | 1.120 |
Why?
| | Aging | 12 | 2024 | 1996 | 1.060 |
Why?
| | Aged | 50 | 2026 | 26432 | 1.040 |
Why?
| | Quality of Life | 12 | 2026 | 3200 | 1.030 |
Why?
| | Creativity | 1 | 2025 | 19 | 0.900 |
Why?
| | Self Care | 2 | 2025 | 396 | 0.860 |
Why?
| | Integrative Medicine | 1 | 2025 | 17 | 0.850 |
Why?
| | High-Intensity Interval Training | 4 | 2026 | 45 | 0.840 |
Why?
| | Drama | 1 | 2024 | 5 | 0.830 |
Why?
| | Spouses | 1 | 2025 | 107 | 0.830 |
Why?
| | Muscle, Skeletal | 8 | 2026 | 1818 | 0.830 |
Why?
| | Middle Aged | 52 | 2026 | 36619 | 0.820 |
Why?
| | Complementary Therapies | 1 | 2025 | 93 | 0.800 |
Why?
| | Health Services Needs and Demand | 1 | 2025 | 287 | 0.770 |
Why?
| | Muscle Strength | 4 | 2026 | 340 | 0.750 |
Why?
| | Humans | 94 | 2026 | 146342 | 0.740 |
Why?
| | Independent Living | 1 | 2024 | 114 | 0.740 |
Why?
| | Collagen Type I | 3 | 2021 | 144 | 0.730 |
Why?
| | Alkaline Phosphatase | 2 | 2021 | 144 | 0.720 |
Why?
| | Ibuprofen | 2 | 2021 | 87 | 0.710 |
Why?
| | Health Education | 1 | 2024 | 346 | 0.660 |
Why?
| | Female | 65 | 2026 | 79499 | 0.650 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 88 | 0.640 |
Why?
| | Poverty | 1 | 2024 | 530 | 0.640 |
Why?
| | Male | 54 | 2026 | 73396 | 0.630 |
Why?
| | HIV Long-Term Survivors | 1 | 2020 | 3 | 0.620 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 125 | 0.610 |
Why?
| | Interleukin-6 | 2 | 2021 | 784 | 0.610 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 344 | 0.590 |
Why?
| | Qualitative Research | 8 | 2025 | 1734 | 0.590 |
Why?
| | Frail Elderly | 7 | 2026 | 141 | 0.580 |
Why?
| | Interleukin-10 | 1 | 2021 | 310 | 0.580 |
Why?
| | Attitude to Health | 2 | 2019 | 421 | 0.570 |
Why?
| | Resistance Training | 4 | 2026 | 186 | 0.560 |
Why?
| | Critical Illness | 1 | 2025 | 908 | 0.540 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 75 | 0.530 |
Why?
| | Preventive Health Services | 1 | 2020 | 154 | 0.530 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 220 | 0.530 |
Why?
| | Physical Fitness | 5 | 2026 | 209 | 0.530 |
Why?
| | Peptides | 3 | 2021 | 992 | 0.510 |
Why?
| | Adiposity | 3 | 2013 | 533 | 0.500 |
Why?
| | Anti-HIV Agents | 7 | 2020 | 914 | 0.490 |
Why?
| | Sarcopenia | 3 | 2026 | 100 | 0.470 |
Why?
| | Perception | 1 | 2019 | 373 | 0.470 |
Why?
| | Adaptation, Physiological | 3 | 2021 | 568 | 0.460 |
Why?
| | Fatigue | 6 | 2026 | 363 | 0.450 |
Why?
| | Cross-Sectional Studies | 14 | 2026 | 5899 | 0.440 |
Why?
| | Hormone Replacement Therapy | 3 | 2018 | 107 | 0.440 |
Why?
| | Dehydroepiandrosterone Sulfate | 3 | 2013 | 43 | 0.430 |
Why?
| | Guidelines as Topic | 2 | 2019 | 267 | 0.430 |
Why?
| | Estrogens | 4 | 2013 | 364 | 0.430 |
Why?
| | Telemedicine | 1 | 2023 | 966 | 0.400 |
Why?
| | Self Efficacy | 4 | 2024 | 418 | 0.390 |
Why?
| | Aged, 80 and over | 11 | 2026 | 8391 | 0.380 |
Why?
| | Sex Factors | 2 | 2018 | 2107 | 0.380 |
Why?
| | Nausea | 2 | 2023 | 111 | 0.350 |
Why?
| | Survivors | 2 | 2014 | 526 | 0.340 |
Why?
| | Inflammation | 3 | 2021 | 2919 | 0.320 |
Why?
| | Bone and Bones | 2 | 2013 | 319 | 0.320 |
Why?
| | Acetaminophen | 1 | 2012 | 268 | 0.300 |
Why?
| | Interviews as Topic | 3 | 2024 | 930 | 0.300 |
Why?
| | Adolescent | 11 | 2025 | 22557 | 0.300 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 2219 | 0.290 |
Why?
| | Health Status | 2 | 2020 | 827 | 0.290 |
Why?
| | Postmenopause | 5 | 2019 | 394 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2025 | 1224 | 0.270 |
Why?
| | HIV-1 | 5 | 2020 | 913 | 0.260 |
Why?
| | Adult | 21 | 2025 | 41087 | 0.260 |
Why?
| | Healthy Aging | 2 | 2024 | 44 | 0.260 |
Why?
| | Absorptiometry, Photon | 5 | 2026 | 278 | 0.250 |
Why?
| | Menopause | 2 | 2021 | 328 | 0.250 |
Why?
| | Cardiorespiratory Fitness | 3 | 2026 | 73 | 0.250 |
Why?
| | Accelerometry | 2 | 2019 | 124 | 0.240 |
Why?
| | Pain | 2 | 2023 | 790 | 0.240 |
Why?
| | Growth Hormone-Releasing Hormone | 1 | 2026 | 19 | 0.240 |
Why?
| | Child | 9 | 2025 | 22693 | 0.230 |
Why?
| | Glucose | 1 | 2011 | 1053 | 0.230 |
Why?
| | Focus Groups | 3 | 2025 | 588 | 0.230 |
Why?
| | Child, Preschool | 7 | 2025 | 11913 | 0.230 |
Why?
| | Motor Activity | 3 | 2014 | 704 | 0.230 |
Why?
| | Qa-SNARE Proteins | 1 | 2025 | 18 | 0.220 |
Why?
| | Radioisotope Dilution Technique | 1 | 2004 | 14 | 0.210 |
Why?
| | Biomarkers | 6 | 2021 | 4340 | 0.210 |
Why?
| | Weight Loss | 4 | 2020 | 858 | 0.210 |
Why?
| | Residence Characteristics | 2 | 2026 | 385 | 0.210 |
Why?
| | Body Water | 1 | 2004 | 23 | 0.210 |
Why?
| | Missouri | 1 | 2024 | 66 | 0.210 |
Why?
| | Cancer Survivors | 2 | 2021 | 348 | 0.210 |
Why?
| | Urine | 1 | 2004 | 63 | 0.210 |
Why?
| | Serum | 1 | 2004 | 58 | 0.210 |
Why?
| | Sports Medicine | 1 | 2026 | 120 | 0.210 |
Why?
| | Chile | 1 | 2024 | 26 | 0.200 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2004 | 30 | 0.200 |
Why?
| | Deuterium | 1 | 2004 | 101 | 0.200 |
Why?
| | Social Stigma | 2 | 2023 | 174 | 0.200 |
Why?
| | Lumbar Vertebrae | 3 | 2018 | 260 | 0.190 |
Why?
| | Text Messaging | 1 | 2025 | 188 | 0.190 |
Why?
| | Intention | 1 | 2024 | 187 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2026 | 1763 | 0.190 |
Why?
| | Heart Rate | 2 | 2024 | 846 | 0.190 |
Why?
| | Down-Regulation | 1 | 2025 | 614 | 0.190 |
Why?
| | Feasibility Studies | 2 | 2025 | 1135 | 0.190 |
Why?
| | Parents | 2 | 2022 | 1394 | 0.190 |
Why?
| | Autophagy | 1 | 2025 | 290 | 0.180 |
Why?
| | Saliva | 1 | 2004 | 256 | 0.180 |
Why?
| | Surveys and Questionnaires | 9 | 2024 | 6073 | 0.180 |
Why?
| | Cognition | 2 | 2025 | 1292 | 0.180 |
Why?
| | Proxy | 1 | 2022 | 37 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2026 | 317 | 0.170 |
Why?
| | Femur | 2 | 2018 | 264 | 0.170 |
Why?
| | Malnutrition | 1 | 2023 | 87 | 0.170 |
Why?
| | Blood Platelets | 1 | 2025 | 382 | 0.170 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 15 | 0.170 |
Why?
| | Symptom Assessment | 1 | 2023 | 138 | 0.170 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 39 | 0.170 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 57 | 0.170 |
Why?
| | Attitude | 1 | 2023 | 253 | 0.170 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.170 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 79 | 0.170 |
Why?
| | Prospective Studies | 3 | 2023 | 8123 | 0.160 |
Why?
| | Raloxifene Hydrochloride | 2 | 2013 | 15 | 0.150 |
Why?
| | Advance Directives | 1 | 2021 | 89 | 0.150 |
Why?
| | Protective Factors | 1 | 2020 | 97 | 0.150 |
Why?
| | Viral Load | 2 | 2020 | 526 | 0.150 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 307 | 0.150 |
Why?
| | Perimenopause | 1 | 2020 | 69 | 0.150 |
Why?
| | Life Expectancy | 1 | 2020 | 72 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2025 | 481 | 0.150 |
Why?
| | Colorado | 3 | 2026 | 4595 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2026 | 881 | 0.140 |
Why?
| | United States | 5 | 2026 | 16136 | 0.140 |
Why?
| | Placebos | 2 | 2011 | 192 | 0.140 |
Why?
| | Cell Phone | 1 | 2020 | 83 | 0.140 |
Why?
| | Health Behavior | 1 | 2024 | 802 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 712 | 0.140 |
Why?
| | DNA Methylation | 1 | 2023 | 725 | 0.140 |
Why?
| | Mexican Americans | 1 | 1999 | 119 | 0.140 |
Why?
| | Housing | 1 | 2019 | 142 | 0.130 |
Why?
| | Blood Glucose | 4 | 2013 | 2360 | 0.130 |
Why?
| | Double-Blind Method | 3 | 2026 | 2070 | 0.130 |
Why?
| | Chronic Disease | 2 | 2021 | 1827 | 0.130 |
Why?
| | Muscle Proteins | 1 | 2019 | 242 | 0.130 |
Why?
| | Insulin | 5 | 2013 | 2525 | 0.120 |
Why?
| | Advance Care Planning | 1 | 2021 | 244 | 0.120 |
Why?
| | Women's Health | 1 | 2019 | 317 | 0.120 |
Why?
| | Pelvic Bones | 1 | 2018 | 137 | 0.120 |
Why?
| | Dietary Proteins | 2 | 2015 | 135 | 0.120 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 314 | 0.120 |
Why?
| | Geriatric Assessment | 3 | 2026 | 244 | 0.120 |
Why?
| | Obesity | 3 | 2016 | 3131 | 0.120 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2016 | 118 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2026 | 11821 | 0.110 |
Why?
| | Physical Therapists | 1 | 2017 | 68 | 0.110 |
Why?
| | Risk Factors | 7 | 2020 | 10921 | 0.110 |
Why?
| | Estradiol | 1 | 2019 | 517 | 0.110 |
Why?
| | Caseins | 1 | 2015 | 20 | 0.110 |
Why?
| | Phenylketonurias | 1 | 2015 | 15 | 0.110 |
Why?
| | Anxiety | 1 | 2023 | 1125 | 0.110 |
Why?
| | Adaptation, Psychological | 2 | 2020 | 721 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 279 | 0.100 |
Why?
| | Diet, Protein-Restricted | 1 | 2013 | 11 | 0.100 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2013 | 33 | 0.100 |
Why?
| | Stress, Psychological | 2 | 2020 | 1171 | 0.100 |
Why?
| | Microbiota | 1 | 2021 | 725 | 0.100 |
Why?
| | Pyridoxine | 1 | 2013 | 37 | 0.100 |
Why?
| | Dietary Supplements | 2 | 2015 | 587 | 0.100 |
Why?
| | Hospitalization | 1 | 2024 | 2475 | 0.100 |
Why?
| | Developmental Disabilities | 1 | 2016 | 281 | 0.100 |
Why?
| | Activities of Daily Living | 1 | 2017 | 442 | 0.100 |
Why?
| | Decision Making | 1 | 2021 | 993 | 0.100 |
Why?
| | Physical Therapy Modalities | 1 | 2017 | 341 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 250 | 0.090 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 769 | 0.090 |
Why?
| | Neoadjuvant Therapy | 1 | 2016 | 475 | 0.090 |
Why?
| | Homocystinuria | 1 | 2013 | 62 | 0.090 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 144 | 0.090 |
Why?
| | Risk Assessment | 2 | 2020 | 3712 | 0.090 |
Why?
| | Thigh | 2 | 2010 | 49 | 0.090 |
Why?
| | Sleep | 1 | 2020 | 896 | 0.090 |
Why?
| | Urea Cycle Disorders, Inborn | 1 | 2012 | 26 | 0.090 |
Why?
| | Young Adult | 3 | 2025 | 14330 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 249 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 139 | 0.090 |
Why?
| | Public Health | 1 | 2017 | 574 | 0.090 |
Why?
| | Sports | 1 | 1994 | 217 | 0.080 |
Why?
| | Depression | 2 | 2019 | 1575 | 0.080 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2011 | 41 | 0.080 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 238 | 0.080 |
Why?
| | Peptide Fragments | 1 | 2015 | 693 | 0.080 |
Why?
| | Amino Acids | 1 | 2015 | 515 | 0.080 |
Why?
| | Prognosis | 1 | 2020 | 4351 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2026 | 3017 | 0.080 |
Why?
| | Osteogenesis | 1 | 2012 | 205 | 0.080 |
Why?
| | Cholesterol, HDL | 1 | 2011 | 201 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2013 | 320 | 0.080 |
Why?
| | Hip | 2 | 2011 | 61 | 0.080 |
Why?
| | Osteoporosis | 1 | 2013 | 240 | 0.080 |
Why?
| | Lipids | 2 | 2013 | 714 | 0.080 |
Why?
| | Subcutaneous Fat | 1 | 2010 | 80 | 0.080 |
Why?
| | Cholesterol, LDL | 1 | 2011 | 363 | 0.070 |
Why?
| | Accidental Falls | 1 | 2012 | 227 | 0.070 |
Why?
| | Cholesterol | 1 | 2011 | 411 | 0.070 |
Why?
| | Time Factors | 6 | 2026 | 7109 | 0.070 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 104 | 0.070 |
Why?
| | Triglycerides | 1 | 2011 | 527 | 0.070 |
Why?
| | Follicle Stimulating Hormone | 2 | 2021 | 265 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2013 | 559 | 0.070 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2008 | 51 | 0.070 |
Why?
| | Research Design | 2 | 2025 | 1143 | 0.070 |
Why?
| | Dyslipidemias | 1 | 2010 | 184 | 0.070 |
Why?
| | Linear Models | 2 | 2008 | 857 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2013 | 3647 | 0.070 |
Why?
| | Area Under Curve | 2 | 2010 | 335 | 0.070 |
Why?
| | Weight Gain | 1 | 2011 | 562 | 0.060 |
Why?
| | Vascular Stiffness | 1 | 2012 | 488 | 0.060 |
Why?
| | Diet | 2 | 2006 | 1273 | 0.060 |
Why?
| | Body Mass Index | 3 | 2013 | 2458 | 0.060 |
Why?
| | Calcium, Dietary | 1 | 2006 | 52 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1432 | 0.060 |
Why?
| | Washington | 1 | 2026 | 157 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 999 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 1999 | 2623 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 417 | 0.050 |
Why?
| | Testosterone | 1 | 2008 | 419 | 0.050 |
Why?
| | Energy Metabolism | 3 | 2013 | 930 | 0.050 |
Why?
| | Florida | 1 | 2023 | 117 | 0.050 |
Why?
| | Rest | 1 | 2004 | 126 | 0.050 |
Why?
| | Europe | 2 | 2015 | 421 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2418 | 0.050 |
Why?
| | C-Peptide | 1 | 2004 | 191 | 0.050 |
Why?
| | Social Support | 2 | 2018 | 646 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2004 | 360 | 0.050 |
Why?
| | Vitamin D | 1 | 2006 | 402 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 280 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 2113 | 0.040 |
Why?
| | Habits | 1 | 2022 | 47 | 0.040 |
Why?
| | Insulin Resistance | 1 | 2010 | 1247 | 0.040 |
Why?
| | Survival Analysis | 2 | 2015 | 1378 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2005 | 642 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2006 | 801 | 0.040 |
Why?
| | Death | 1 | 2021 | 129 | 0.040 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2000 | 116 | 0.040 |
Why?
| | Actigraphy | 1 | 2020 | 148 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1888 | 0.040 |
Why?
| | Comorbidity | 1 | 2024 | 1665 | 0.040 |
Why?
| | Meiosis | 1 | 2000 | 102 | 0.040 |
Why?
| | Premenopause | 1 | 2020 | 130 | 0.040 |
Why?
| | DNA Transposable Elements | 1 | 2000 | 125 | 0.040 |
Why?
| | Age Factors | 1 | 2026 | 3347 | 0.030 |
Why?
| | Postprandial Period | 1 | 1999 | 114 | 0.030 |
Why?
| | Family | 1 | 2023 | 690 | 0.030 |
Why?
| | Mitochondria | 1 | 2025 | 997 | 0.030 |
Why?
| | Counseling | 1 | 2021 | 406 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3125 | 0.030 |
Why?
| | Phenotype | 1 | 2026 | 3206 | 0.030 |
Why?
| | Halothane | 1 | 1997 | 8 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 154 | 0.030 |
Why?
| | Myosin Light Chains | 1 | 1997 | 29 | 0.030 |
Why?
| | DNA Damage | 1 | 2000 | 439 | 0.030 |
Why?
| | Affect | 1 | 2020 | 318 | 0.030 |
Why?
| | Acetylcholine | 1 | 1997 | 209 | 0.030 |
Why?
| | Muscle, Smooth | 1 | 1997 | 152 | 0.030 |
Why?
| | Axilla | 1 | 2016 | 51 | 0.030 |
Why?
| | Health Services for the Aged | 1 | 2017 | 73 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2000 | 411 | 0.030 |
Why?
| | Sentinel Lymph Node | 1 | 2016 | 49 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 19 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 2000 | 584 | 0.030 |
Why?
| | Turkey | 1 | 2015 | 20 | 0.030 |
Why?
| | Trachea | 1 | 1997 | 253 | 0.030 |
Why?
| | Professional Role | 1 | 2017 | 172 | 0.030 |
Why?
| | Liver | 1 | 2004 | 1864 | 0.030 |
Why?
| | Isometric Contraction | 1 | 1997 | 200 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2016 | 174 | 0.030 |
Why?
| | Smartphone | 1 | 2016 | 103 | 0.030 |
Why?
| | Infant | 3 | 2015 | 10114 | 0.030 |
Why?
| | World Health Organization | 1 | 2015 | 104 | 0.030 |
Why?
| | Phenylalanine | 1 | 2015 | 69 | 0.030 |
Why?
| | Tracheostomy | 1 | 2016 | 136 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1707 | 0.030 |
Why?
| | Body Constitution | 1 | 1994 | 51 | 0.030 |
Why?
| | Betaine | 1 | 2013 | 66 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.020 |
Why?
| | Aging, Premature | 1 | 2013 | 18 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2013 | 47 | 0.020 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 43 | 0.020 |
Why?
| | Homocysteine | 1 | 2013 | 152 | 0.020 |
Why?
| | Methionine | 1 | 2013 | 160 | 0.020 |
Why?
| | Amino Acids, Essential | 1 | 2012 | 13 | 0.020 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2012 | 39 | 0.020 |
Why?
| | Dietetics | 1 | 2012 | 24 | 0.020 |
Why?
| | Muscles | 1 | 2013 | 330 | 0.020 |
Why?
| | Nutritional Support | 1 | 2012 | 39 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2016 | 1488 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 164 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2015 | 6460 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 278 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2012 | 206 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2016 | 711 | 0.020 |
Why?
| | Bone Remodeling | 1 | 2011 | 71 | 0.020 |
Why?
| | United Kingdom | 1 | 2012 | 377 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3926 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 495 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 212 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 6077 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2599 | 0.020 |
Why?
| | Weight Reduction Programs | 1 | 2011 | 140 | 0.020 |
Why?
| | Contraceptive Agents | 1 | 2010 | 65 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2012 | 721 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1137 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 779 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 788 | 0.020 |
Why?
| | Executive Function | 1 | 2013 | 463 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 790 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 1149 | 0.020 |
Why?
| | Mice | 1 | 2025 | 18297 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 1354 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 931 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1150 | 0.010 |
Why?
| | Patient Compliance | 1 | 2010 | 589 | 0.010 |
Why?
| | Incidence | 1 | 2012 | 2936 | 0.010 |
Why?
| | Buttocks | 1 | 2005 | 14 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2219 | 0.010 |
Why?
| | Animals | 2 | 2025 | 38107 | 0.010 |
Why?
| | Abdomen | 1 | 2005 | 142 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2011 | 5439 | 0.010 |
Why?
| | Aminohydrolases | 1 | 2000 | 3 | 0.010 |
Why?
| | Gene Conversion | 1 | 2000 | 7 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 17438 | 0.010 |
Why?
| | MutS Homolog 2 Protein | 1 | 2000 | 12 | 0.010 |
Why?
| | Genes, Fungal | 1 | 2000 | 55 | 0.010 |
Why?
| | Endonucleases | 1 | 2000 | 35 | 0.010 |
Why?
| | DNA Repair Enzymes | 1 | 2000 | 29 | 0.010 |
Why?
| | Pyrophosphatases | 1 | 2000 | 28 | 0.010 |
Why?
| | Alcohol Oxidoreductases | 1 | 2000 | 61 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2010 | 2786 | 0.010 |
Why?
| | Fungal Proteins | 1 | 2000 | 137 | 0.010 |
Why?
| | Guanosine Triphosphate | 1 | 1997 | 88 | 0.010 |
Why?
| | Cell Membrane Permeability | 1 | 1997 | 88 | 0.010 |
Why?
| | Alleles | 1 | 2000 | 907 | 0.010 |
Why?
| | Cytosol | 1 | 1997 | 215 | 0.010 |
Why?
| | Base Sequence | 1 | 2000 | 2123 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2000 | 2838 | 0.010 |
Why?
| | Dogs | 1 | 1997 | 517 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1997 | 1041 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2000 | 1242 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1553 | 0.010 |
Why?
| | Eating | 1 | 1995 | 386 | 0.010 |
Why?
| | Phosphorylation | 1 | 1997 | 1724 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2000 | 1468 | 0.010 |
Why?
| | Transcription Factors | 1 | 2000 | 1730 | 0.010 |
Why?
| | Calcium | 1 | 1997 | 1181 | 0.010 |
Why?
|
|
Jankowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|